A5012771029- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Cytokine Signaling Pathways and Interactions
- Cancer Cells and Metastasis
- Melanoma and MAPK Pathways
- Cancer-related Molecular Pathways
- Retinoids in leukemia and cellular processes
- Protein Kinase Regulation and GTPase Signaling
- Cell death mechanisms and regulation
- Advanced Breast Cancer Therapies
- Cell Adhesion Molecules Research
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Endoplasmic Reticulum Stress and Disease
- 14-3-3 protein interactions
- Cancer, Lipids, and Metabolism
- Immunotherapy and Immune Responses
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Mechanisms of cancer metastasis
- PI3K/AKT/mTOR signaling in cancer
- Breast Cancer Treatment Studies
- Cancer therapeutics and mechanisms
- Wnt/β-catenin signaling in development and cancer
Houston Methodist
2023-2025
University of Houston
2010-2023
University of Pennsylvania
2018-2023
IST Research
2023
University of Ioannina
2006-2009
The University of Texas System
1998
The University of Texas Health Science Center at San Antonio
1998
Aberrant Notch signaling is implicated in several cancers, including breast cancer. However, the mechanistic details of specific receptors and function ligand-mediated that promote cancer remains elusive. In our studies we show DLL1, a ligand, significantly overexpressed ERα+ luminal Intriguingly, DLL1 overexpression correlates with poor prognosis cancer, but not other subtypes addition, this effect to as ligands (DLL3, JAGGED1, JAGGED2) do influence clinical outcome patients. Genetic...
Epithelial to mesenchymal transition (EMT) is associated with the basal-like breast cancer phenotypes. Sixty percent of cancers have been shown express wild-type estrogen receptor beta (ERβ1). However, it still unclear whether ERβ expression related EMT, invasion and metastasis in cancer. In present study, we examined ERβ1 through regulating EMT can influence cancers. Basal-like cells (MDA-MB-231 Hs578T), which was either overexpressed or down-regulated were analyzed for their ability...
Abstract Resistance to radiotherapy is a major obstacle for effective cancer treatment. Both cancer-associated fibroblasts (CAF) within the tumor microenvironment (TME) and Notch signaling are implicated in radioresistance, but their potential interrelationship unclear. Here, we report that irradiated samples obtained from luminal breast patient tumors express higher levels of ligand Dll1 have greater number αSMA- FAP-expressing activated CAFs. Single cell transcriptomic profiles further...
The growth of many human breast tumors requires the proliferative effect estrogen acting via receptor α (ERα). ERα signaling is therefore a clinically important target for cancer prevention and therapeutics. Although extensively studied, mechanism by which promotes proliferation remains to be fully established. We observed an up-regulation transcript encoding pH-sensitive two-pore domain potassium channel KCNK5 in screen genes stimulated 17β-estradiol (E2) ERα(+) cell lines MCF-7 T47D. mRNA...
Most (80%) of the triple-negative breast cancers (TNBCs) express mutant p53 proteins that acquire oncogenic activities including promoting metastasis. We previously showed wild-type ERβ (ERβ1) impedes epithelial to mesenchymal transition (EMT) and decreases invasiveness TNBC cells. In present study we searched for signaling pathways ERβ1 uses inhibit EMT invasion in show binds opposes transcriptional activity at promoters genes regulate p63 transcriptionally cooperates with also ERβ1....
Estrogen receptor (ER) β (ERβ) is the second ER subtype that mediates effects of estrogen in target tissues along with ERα represents a validated biomarker and for endocrine therapy breast cancer. was only known until 1996 when discovery ERβ opened new chapter endocrinology prompted thorough reevaluation signaling paradigm. Unlike oncogenic ERα, has been proposed to function as tumor suppressor cancer, extensive research underway uncover full spectrum activities elucidate its mechanism...
Multiple myeloma (MM) is an incurable disease despite initial response-rate of >60% with conventional or high-dose chemotherapy using glucocorticosteroids (i.e. dexamethasone), alkylating agents melphalan). Although these are capable inducing complete remission (CR) in >50% MM patients, resistance develops rapidly, >90% within 2 years treatment. Therefore, there a need for new drugs the treatment relapsing and refractory patients. Gemcitabine (GEM) pyrimidine analog that blocks DNA...
Several pharmaceutical agents produce ethanol intolerance, which is often depicted as disulfiram-like reaction. As in the case with disulfiram, underlying mechanism believed to be accumulation of acetaldehyde blood, due inhibition hepatic aldehyde dehydrogenases. In present study, chloramphenicol, furazolidone, metronidazole, and quinacrine, are reported a reaction, well were administered Wistar rats activities alcohol dehydrogenases (1A1 2) determined. The expression dehydrogenase 2 was...
Background: Inflammatory breast cancer (IBC) is a rare subtype of accounting for 7% cancer-related fatalities. There an urgent need to develop new targeted treatments IBC. The progression IBC has been associated with alterations in growth factor and cytokine signaling; however, the function LIF (leukemia inhibitory factor)/LIFR receptor) pathway remains unknown. This study evaluated role LIFR signaling tested efficacy inhibitor EC359 treating Methods: utility using inhibition as treatment...
Abstract Background: Inflammatory breast cancer (IBC) is a rare and aggressive form of characterized by rapid progression, early metastatic potential, distinct clinical pathological features. The main treatment includes systemic cytotoxic therapy, surgery, radiation. There need for novel targeted therapies to improve patients’outcomes. Inducible nitric oxide synthase (iNOS) mediator various cancers including cancer. pan-NOS inhibitor L-NMMA has been studied in preclinical settings, primarily...
Abstract Background: Inflammatory breast cancer (IBC) is a rare subtype of affecting 2-4% the U.S. population. With incidence being quite low, IBC responsible for 7% related mortality often younger women. The only currently approved options treatment are surgical resection, chemotherapy, and radiation. Novel therapeutic targets desperately needed generation new therapeutics. progression has been linked to growth factor cytokine signaling abnormalities. In previous studies, LIF/LIFR axis...
Abstract Purpose of the study: The goal this study is to understand how targeting inducible Nitric Oxide Synthase 2 (NOS2) may alter ovarian cancer tumor microenvironment. NOS2 part many proinflammatory pathways and plays a key role in immune response regulation cell proliferation. By combining pan-NOS inhibitor L-NMMA with conventional Cisplatin administration, we want convert environment from “cold” or non-responsive “hot” responsive chemotherapy. Experimental procedures: We established an...
Abstract Purpose of the study: Obesity fosters an adverse tumor microenvironment (TME) characterized by immune suppression, metabolic dysfunction, and pro-tumoral cytokines. Elevated nitric oxide (NO) levels produced inducible nitic synthase (iNOS) exacerbate vascular dysfunction metastasis. This study investigates whether combining NOS inhibitor N(G)-monomethyl-L-arginine (L-NMMA) with docetaxel enhances antitumor efficacy in obese TNBC model. Experimental Procedures: An orthotopic model...
Upregulation of estrogen receptor beta (ERβ) in breast cancer cells is associated with epithelial maintenance, decreased proliferation and invasion, a reduction the expression has been observed invasive tumors. However, proof an association between loss ERβ carcinogenesis still missing.To study role oncogenesis, we generated mouse conditional mutants specific inactivation p53 mammary gland epithelium. For epithelium-specific knockout p53, F/F mice were crossed to transgenic that express Cre...
// Igor Bado 1 , Eric Pham 2 Benjamin Soibam 3 Fotis Nikolos Jan-Åke Gustafsson 1, 4 and Christoforos Thomas Department of Biology Biochemistry, Center for Nuclear Receptors Cell Signaling, University Houston, Texas, USA Computer Science Engineering Technology, Houston-Downtown, Huston, Innovative Medicine, Biosciences Nutrition, Karolinska Institutet, Huddinge, Sweden Correspondence to: Thomas, email: thomaschristoforos@gmail.com Keywords: estrogen receptor β; p53; breast cancer; DNA damage...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. In addition to aberrant growth factor signaling, dysregulation other pathways, such as those mediated by estrogens and their receptors, has been linked NSCLC initiation progression. Although expression wild-type estrogen receptor β (ERβ1) associated with prolonged disease-free survival in patients NSCLC, molecular mechanism that accounts for this correlation unknown. Here, upregulation ERβ1 reduced...